According to the Zhitong Finance App, Ark Kenke (06086) announced interim results for the six months ended June 30, 2026. The group achieved revenue of 1,824 billion yuan, an increase of 22.15% year on year; adjusted net profit of 18.708 million yuan, an increase of 6.39% year on year; and profit per share of 0.01 yuan.
During the reporting period, the Group relied on the “Xingshi” Big Language Model (Xingshi Big Model) to continuously refine our AI solutions and expand the deployment of AI on our platform, including applications in key areas such as chronic disease management, auxiliary diagnosis and operation management, to optimize service processes, improve user experience, and enhance operational efficiency. To support the continuous development, large-scale application and commercial exploration of AI technology, the Group completed placement and subscription transactions in February 2026, raising a net proceeds of approximately HK$144 million.
As of June 30, 2026, our user base reached 59.8 million registered users (up 13.2% year over year), while in the 12 months ended June 30, 2026, the average monthly active users increased by 23.1% to 14.7 million. We have also continued to expand our network of medical service providers to nearly 282,000 registered doctors, and strengthened cooperation with more than 1,800 suppliers and more than 1,000 pharmaceutical companies.
For the six months ended June 30, 2026, the Group's revenue increased 22.2% year on year to $1,824.5 billion, and adjusted net profit (measured in non-Hong Kong financial reporting standards) reached $18.7 million, up 6.4% from $17.6 million in the same period in 2025, and continued to be profitable. Furthermore, the Group continues to generate positive cash flow from operating activities, reflecting the steady expansion of business scale while operating efficiency continues to improve and costs are effectively controlled, laying a solid foundation for long-term growth.